Last reviewed 2026-04-20 · How we verify

Test formulation (Treatment C) (test-formulation-treatment-c)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pain
• Headache
• Loss of appetite
• Upper respiratory tract infection
• Vomiting
• Redness
• Swelling
• Ecchymosis
• Irritability
• Fever (axillary temperature >=37.5°C)
• Induration
• Drowsiness

Key clinical trials

• Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
• Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial (PHASE3)
• A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults (PHASE1)
• Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers (PHASE1)
• A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults (PHASE1)
• Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 (PHASE1)
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State. (PHASE1)
• A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Test formulation (Treatment C) CI brief — competitive landscape report
• Test formulation (Treatment C) updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI